We are live on ! Find out more
DC

Decheng Capital Portfolio holdings

AUM $661M
1-Year Est. Return 299.97%
This Fund
S&P 500
This Quarter Est. Return
+23.46%
1 Year Est. Return
+299.97%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$396M
AUM Growth
+$39.5M
Cap. Flow
+$14.4M
Cap. Flow %
3.63%
Top 10 Hldgs %
92.38%
Holding
28
New
1
Increased
3
Reduced
8
Closed
3

Top Buys

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$31M
2
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$407K
3
RZLT icon
Rezolute
RZLT
+$222K
4
KRYS icon
Krystal Biotech
KRYS
+$147K

Top Sells

Rank Stock Value
1
RCUS icon
Arcus Biosciences
RCUS
+$5.54M
2
CYTK icon
Cytokinetics
CYTK
+$4.02M
3
LEGN icon
Legend Biotech
LEGN
+$2.59M
4
BNTX icon
BioNTech
BNTX
+$1.82M
5
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$1.08M

Sector Composition

Rank Sector Weight
1 Healthcare 99.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BNTX icon
26
BioNTech
BNTX
$23.4B
– –
-20,000
Closed -$1.82M
CYTK icon
27
Cytokinetics
CYTK
$10.8B
– –
-100,000
Closed -$4.02M
VERA icon
28
Vera Therapeutics
VERA
$2.39B
– –
-4,495
Closed -$108K
1
2

Similar funds

FAM
Fulcrum Asset Management London, United Kingdom $662M AUM 48.09% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
HIG
Heritage Investment Group Pompano Beach, Florida $661M AUM 14.84% 1-Year Est. Return
RCG
Regatta Capital Group El Segundo, California $661M AUM 17.85% 1-Year Est. Return
FM
Freemont Management Vaud, Switzerland $661M AUM 60.48% 1-Year Est. Return
ACM
Arosa Capital Management Miami Beach, Florida $660M AUM 210.26% 1-Year Est. Return
AWA
Artemis Wealth Advisors New York $662M AUM 39.67% 1-Year Est. Return
UCMOK
United Capital Management of KS Salina, Kansas $660M AUM 50.85% 1-Year Est. Return

Decheng Capital's Q2 2025 Portfolio in Review

As of Q2 2025, Decheng Capital held 28 positions worth $396M, up 11% from $356M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Decheng Capital deployed $14.4M of net new capital in Q2 2025, opening 1 new position and adding to 3 existing holdings. Its largest new stake was Rezolute: 59,900 shares worth $267K.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Arcus Biosciences, an estimated $5.54M trimmed.

  • Decheng Capital's largest Q2 2025 buy was Rezolute: 59,900 shares worth $267K.
  • Decheng Capital added most to Arcellx in Q2 2025, an estimated $31M increase.
  • Decheng Capital's biggest Q2 2025 reduction was Arcus Biosciences, cutting an estimated $5.54M.
  • Decheng Capital fully exited Cytokinetics in Q2 2025, selling an estimated $4.02M.
  • Decheng Capital's ten largest holdings make up 92% of its $396M portfolio in Q2 2025.
  • Decheng Capital opened 1 new position and closed 3 in Q2 2025.
  • Decheng Capital's portfolio value rose 11% quarter-over-quarter to $396M.

Based on Decheng Capital's 13F filing for Q2 2025, filed 13 Aug 2025.